BioPharma Resources

Investigational drug · Phase 2

ION337

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Dravet Syndrome.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "ION337"

First trial start

2026

May 21, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ION337", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Dravet Syndrome

Approved drugs for the same conditions: Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "ION337" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Dravet Syndrome

  • LP352bexicaserinPhase 34 trials

    Longboard Pharmaceuticals · Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox-Gastaut Syndrome

  • Clemizole HClEPX-100Phase 32 trials

    Epygenix · Dravet Syndrome, Lennox Gastaut Syndrome

  • zorevunersenSTK-001Phase 32 trials

    Stoke Therapeutics, Inc · Dravet Syndrome

  • ETX101Phase 23 trials

    Encoded Therapeutics · Dravet Syndrome

  • BMB-101Phase 22 trials

    Bright Minds Biosciences Pty Ltd · Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Ionis Pharmaceuticals.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.